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ABO-incompatible (ABOi) kidney transplantation has long been considered a contrain-
dication to successful kidney transplantation. During the last 25 years, increasing organ 
shortage enforced the development of strategies to overcome the ABO antibody barrier. 
In the meantime, ABOi kidney transplantation has become a routine procedure with 
death-censored graft survival rates comparable to the rates in compatible transplan-
tations. Desensitization is usually achieved by apheresis and B cell-depleting therapies 
that are accompanied by powerful immunosuppression. Anti-A/B antibodies are aimed 
to be below a certain threshold at the time of ABOi kidney transplantation and during the 
first 2 weeks after surgery. Thereafter, even a rebound of anti-A/B antibodies does not 
appear to harm the kidney transplant, a phenomenon that is called accommodation, but 
is poorly understood. There is still concern, however, that infectious complications such 
as viral disease, Pneumocystis jirovecii pneumonia, and severe urinary tract infections 
are increased after ABOi transplantations. Recent data from the Collaborative Transplant 
Study show that during the first year after kidney transplantation, one additional patient 
death from an infectious complication occurs in 100 ABOi kidney transplant recipients. 
Herein, we review the recent evidence on ABOi kidney transplantation with a focus on 
desensitization strategies and respective outcomes.
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inTRODUCTiOn
In an earlier publication from 1955, Hume et al. expressed their skepticism on the feasibility of ABO-
incompatible (ABOi) kidney transplantations: “… we do not feel that renal transplantation in the 
presence of blood incompatibility is wise” (1). Since then, major ABO incompatibility has been con-
sidered a contraindication to kidney transplantation. A major breakthrough came in 1982, with the 
first large study on ABOi kidney transplantation by Alexandre et al. from Belgium (2, 3). Successful 
desensitization was achieved by repeated plasmapheresis (PP), splenectomy, donor thrombocyte 
transfusion, and infusion of A or B trisaccharide, together with intensified immunosuppression. 
One-year graft survival in this study was a remarkable 75%. This led to a wider utilization of ABOi 
kidney transplantations, first in Japan from the late 1980s, in the US from the mid 1990s, and in Europe 
from the early 2000s. While, even today, kidney transplantation is best performed in the absence of 
(major) ABO incompatibility, a large end-stage kidney disease population and an increasing organ 
shortage result in waiting times for a deceased donor kidney transplant exceeding 5 years in some 
countries such as Germany. One possibility to reduce the waiting time is the transplantation across 
ABO antibody barriers. Theoretically, the number of kidney transplantations from living donors can 
be increased by up to 30% when patients are transplanted across the ABO antibody barrier. With 
currently existing protocols, as many as 90% of patients with an ABOi living donor may effectively 
FigURe 1 | Overview of desensitization protocols for ABO-incompatible (ABOi) living donor kidney transplantation. (A) Scheme for a standard 
desensitization protocol performed by the majority of centers with modifications in the utilization of desensitization devices, and (B) desensitization protocol for 
ABOi living donor kidney transplantation at the University of Heidelberg. Anti-CD20 therapy is usually performed with rituximab 375 mg/m2, anti-IL-2R therapy is 
performed with basiliximab 20 mg [modified from Ref. (8)]. IA, immunoadsorption; IVIg, intravenous immunoglobulin; PP, plasmapheresis.
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be desensitized and transplanted. The aim of desensitization 
protocols is the reduction and maintenance of anti-A/B antibod-
ies (isoagglutinins) during the first 2 weeks after transplantation 
below a threshold that is considered to be safe (e.g., <1:32 in tube 
technique). Thereafter, even when anti-A/B antibodies recur at 
high levels they will not harm the kidney transplant, a phenom-
enon that is called accommodation. In recent years, graft survival 
rates after ABOi kidney transplantation nearly equaled those after 
ABO-compatible (ABOc) procedures.
Herein, we review the latest efforts and results in kidney 
transplantation across the ABO antibody barrier.
BLOOD gROUP AnTigenS  
AnD AnTiBODieS
The ABO antigen system consists of oligosaccharides that are 
predominantly expressed on red blood cells and are also found 
on endothelial cells, tubuli, and glomeruli making the ABO 
antigen system important for kidney transplantation. Patients 
with different blood groups differ with respect to their antigen 
density on erythrocytes. Compared to blood group A1 and blood 
group B individuals, blood group A2 recipients, who make up 
20% of all Caucasian individuals with blood group A, have a low 
expression of blood group antigen molecules (30–50%) on the 
surface of erythrocytes, which is believed to be responsible for 
the lower immunogenicity of organs from blood group A2 donors 
(4, 5). ABOi kidney transplantation with A2 organs has been 
accomplished with standard immunosuppressive therapy with-
out any additional measures (6). Of interest, anti-A/B antibodies 
are formed upon contact with gut bacteria during early infancy. 
Naturally occurring anti-A/B antibodies are predominantly of the 
IgM class but especially in blood group O individuals they also 
consist of IgG and IgA class (7). While the pathogenic importance 
of anti-A/B antibodies in solid organ transplantation is well 
known, the relative contribution of the different immunoglobulin 
isotypes and their subclasses to organ rejection remains to be 
elucidated.
DeSenSiTiZATiOn FOR ABOi KiDneY 
TRAnSPLAnTATiOn
Despite the absence of a generally accepted desensitization pro-
tocol for the transplantation across the ABO antibody barrier, 
all currently proposed strategies share some common principles 
(Figure 1A).
These include together with a powerful maintenance immu-
nosuppression one or more of the following:
 (1) Anti-A/B antibody depletion at the time of transplantation 
using PP, double-filtration PP/membrane filtration, or selec-
tive or unselective immunoadsorption (IA)
 (2) Modulation of the recipient’s immune system by the use of 
intravenous immunoglobulins (IVIgs)
 (3) Reduction of the B lymphocyte pool by splenectomy, or more 
recently by the anti-CD20 antibody rituximab
 (4) Prevention of the deleterious consequences of complement 
activation upon anti-A/B antibody binding to the graft 
endothelium.
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Antibody Depletion by  
extracorporal Treatment
Antibody removal strategies may be divided into methods that 
completely remove plasma proteins such as PP, methods that 
remove only a specific fraction of the plasma proteins including 
the immunoglobulins (such as membrane separation), and more 
specific methods such as unselective or selective IA. While PP 
is the preferred antibody removal strategy in the US, membrane 
separation is popular in Japan. Unselective and selective IAs are 
often used in Europe.
Selective anti-A/B antibody removal is feasible by the 
Glycosorb columns that contain synthetic terminal trisaccharide 
A or B blood group antigen linked to a sepharose matrix. In 
addition, they may also reduce total IgG as well as IgG against 
polysaccharide antigens such as anti-Pneumococcus IgG (9). In 
a recent analysis, Wahrmann et al. found single treatments with 
unselective IA to be more effective than with selective anti-A/B 
antibody columns in removing anti-A/B IgG (median reduction 
to 28 versus 59% of baseline, P < 0.001) (10). In contrast, unselec-
tive IA was less effective in the removal of anti-A/B antibodies 
of the IgM (74 versus 30%, P <  0.001) and IgG3 subclass (72 
versus 42%, P < 0.05). The same group found that a combination 
of membrane separation and unselective IA effectively removed 
IgG and IgM antibodies and effector molecules such as comple-
ment C1q component (11). No significant differences were 
found in clinical studies that compared the impact of different 
IA strategies on clinical outcomes, including anti-A/B antibody 
reduction, survival, kidney function, rejection episodes, or 
complications (12).
intravenous immunoglobulins
Intravenous immunoglobulins are given by many centers before 
ABOi kidney transplantation to prevent the anti-A/B antibody 
rebound in the early phase after transplantation. In addition, 
IVIg infusion is believed to reduce infectious complications by 
substituting depleted immunoglobulins. As a note of caution, 
IVIg preparations contain IgG antibodies directed against A/B 
antigens and can effectively increase anti-A/B antibody titers 
upon administration (12, 13).
B-Cell Depletion by Splenectomy  
or Rituximab
Before the introduction of pharmacological anti-B cell therapies, 
splenectomy was an integral component for the reduction of the 
B lymphocyte pool prior to ABOi kidney transplantation. Due 
to the surgical risk and increased risk of sepsis, splenectomy 
was gradually substituted by the anti-CD20 antibody rituximab. 
More recently, several groups completely abandoned anti-B cell 
therapies from their protocols. Flint et al. reported on 37 patients 
from Melbourne who underwent ABOi kidney transplantation 
after antibody removal by PP (14). Transplantation was accom-
plished by the use of standard immunosuppressive therapy 
without rituximab when the patient had reached an anti-A/B 
antibody titer of less than 1:32 (tube method). Patient and graft 
survival in this cohort was 100% after a median of 26  months 
after transplantation. Two antibody-mediated rejection episodes 
were successfully reversed. We observed in the Collaborative 
Transplant Study (CTS) a higher rate of death-censored graft 
loss in ABOi kidney transplant recipients when rituximab was 
omitted (see below) (15).
inhibition of Complement Activation
An emerging new concept in the transplantation across ABO 
antibody barriers is the inhibition of complement activation upon 
binding of antibodies to the allograft endothelium. Biglarnia et al. 
described an intentional simultaneous ABOi kidney pancreas 
transplantation (16). Severe antibody-mediated rejection in this 
patient during anti-A/B antibody rebound was successfully treated 
by inhibiting the assembly of the membrane attack complex by 
eculizumab. Stegall et al. performed a single center study to evalu-
ate the efficacy of eculizumab added to conventional therapy in 
the prevention of antibody-mediated rejection after ABOi living 
donor kidney transplantation (unpublished, NCT01095887). 
Patients received eculizumab at the time of transplantation, on 
day 1 after surgery and weekly thereafter for 4 weeks. The study 
was terminated after only six patients due to poor enrollment. 
Two of the six patients reached the primary study endpoint of 
antibody-mediated rejection after 3  months and two allografts 
had to be removed during the study period. Therefore, results 
on the use of eculizumab after ABOi kidney transplantation are 
inconclusive.
DeSenSiTiZATiOn PROTOCOLS AnD 
SURvivAL AFTeR ABOi Living DOnOR 
KiDneY TRAnSPLAnTATiOn
Table S1 in Supplementary Material gives an overview over stud-
ies on ABOi kidney transplantation. The largest cohort of patients 
after ABOi kidney transplantation with the longest follow-up of 
more than 20 years is reported from Japan. Most patients were 
desensitized by double-filtration PP, and splenectomy was more 
recently replaced by the anti-CD20 antibody rituximab. For the 
most recent area from 2001 to 2010, patient and graft survival 
rates for the 1,427 analyzed patients were an excellent 98 and 
96% for the first year, and 91 and 83% after 9 years, respectively 
(17). Data from the Scientific Registry of Transplant Recipients 
on the outcomes of 738 ABOi kidney transplantations that were 
performed between 1995 and 2010 in the US have recently been 
published (18). Most patients were desensitized by PP and low-
dose IVIg. The cumulative incidence of graft loss during the first 
year after transplantation was 5.9% in ABOi as compared to only 
2.9% in ABOc transplantations and occurred mainly during the 
first 2 weeks after surgery due to rejection. In 2003, Tydén et al. 
from Sweden published a protocol for ABOi transplantation that is 
based on recipient desensitization by selective IA using Glycosorb 
columns (19). In addition, splenectomy was replaced by the anti-
CD20 antibody rituximab. This protocol led to a renaissance of 
ABOi kidney transplantation in Europe. Recently, Genberg et al. 
published their extended experience with this protocol (20). Of 
45 patients desensitized for ABOi kidney transplantation, 43 were 
eventually transplanted between September 2001 and May 2010 
(96%). Overall patient and graft survival after a mean follow-up 
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of 4.5 years was 93 and 91%, respectively. None of the patients 
experienced early acute antibody-mediated rejection that could 
be linked to anti-A/B antibodies. Recently, the Freiburg group 
from Germany compared the results of 100 ABOi kidney trans-
plantations performed between April 1, 2004, and October 28, 
2014, with the results of 248 ABOc transplantations performed 
during the same time period (21). Using the Stockholm protocol, 
they achieved in recipients of ABOi transplants a 10-year patient 
and death-censored graft survival of 99 and 94%, respectively, 
which did not differ significantly from the 80 and 88% survival 
rates, respectively, in recipients of ABOc transplants. The rates 
for antibody- and T-cell-mediated rejections were also not 
significantly different. A study from the UK showed similar 
death-censored graft survival in 62 patients 3 years after ABOi 
kidney transplantation when compared to ABOc controls (22). 
However, patient survival in ABOi transplant recipients was 
reduced due to infectious complications, mostly Pneumocystis 
jirovecii pneumonia.
Since 2006, at our center in Heidelberg, we have been using a 
protocol for desensitization of ABOi kidney transplant candidates 
that is very similar to the Swedish protocol (Figure 1B) (8, 12). 
The major difference is the use of unselective instead of selec-
tive IA, allowing also the desensitization for HLA-incompatible 
living donor kidney transplantation. Further differences are 
the omission of IVIg application and a variable number of IA 
treatments depending on the strength of anti-A/B antibody. To 
remove pathogenically relevant anti-A/B antibodies of the IgM 
class more efficiently, at least one additional PP treatment was 
performed in all patients the day before surgery as of August 2012 
(23). An early analysis of ABOi kidney transplantations showed 
successful desensitization of 12 patients after a median of six IA 
treatments (12). Anti-A/B titer reduction with unselective IA 
was comparable to that of a historical control group that received 
selective IA. In a more recent analysis, we compared 34 ABOi kid-
ney transplant recipients who were desensitized with unselective 
IA to 68 matched, standard risk living donor kidney recipients 
(23). After a median postoperative follow-up of 22 months, graft 
survival in ABOi kidney transplant recipients was insignificantly 
lower compared to standard risk recipients (P =  0.05). One of 
the two patient deaths in the ABOi kidney transplant recipients 
was due to P. jirovecii pneumonia at postoperative day 169. This 
patient death may be attributable to intensified immunosuppres-
sion that was applied during desensitization including rituximab. 
Other important differences between ABOi and standard risk 
kidney recipients were a higher incidence of BK virus replication 
(>104 copies/mL plasma, 21 versus 6%, P = 0.04) and BK virus 
nephropathy (SV 40 positive in biopsy, 12 versus 0%, P = 0.01) 
and a higher prevalence of colonization with multidrug-resistant 
bacteria (15 versus 1%, P = 0.02).
ReSULTS FROM THe CTS
We recently published 3-year outcomes of 1,420 ABOi kidney 
transplant recipients who were transplanted at 101 different 
centers between 2005 and 2012 (15). Patients were compared to 
a matched group of ABOc kidney transplant recipients and to all 
ABOc kidney transplant recipients from centers that performed 
at least five ABOi procedures. Overall graft, death-censored 
graft, and patient survival were not statistically significant dif-
ferent between the groups. Early patient survival was reduced 
in ABOi kidney transplant recipients due to a higher rate of 
early infection-associated death (P  =  0.037 versus matched 
controls and P < 0.001 versus center controls). Specifically, one 
additional death per 100 patients occurred in the first year after 
ABOi kidney transplantation from an infectious complication. 
Figure  2 provides the updated results for this cohort of 1,420 
ABOi kidney transplant recipients (15). Of note, a trend toward 
better 3-year death-censored graft survival in patients receiving 
anti-CD20 therapy (P = 0.081) in the meantime has become sta-
tistically significant after longer follow-up (P = 0.009, Figure 2C), 
suggesting a need for anti-B cell therapies in the setting of ABO 
incompatibility.
COMPLiCATiOnS AnD HURDLeS OF  
ABOi KiDneY TRAnSPLAnTATiOn
Accomodation versus Rejection
In contrast to transplantation in the HLA-sensitized patient, 
accommodation appears to be a frequent phenomenon after ABOi 
kidney transplantations and is often associated with C4d deposi-
tion in peritubular capillaries of allograft biopsies. An accom-
modation phenotype may be achieved by the controlled anti-A/B 
antibody exposure to antigens in the early phase after kidney 
transplantation. About 2 weeks after successful transplantation, 
accommodation is established and even high anti-A/B antibody 
exposure does not harm the kidney transplant. Local upregula-
tion of complement regulatory proteins, like CD45, CD55, and 
CD59, as a consequence of anti-A/B antibody-dependent inacti-
vation of ERK1/2 signaling pathway are discussed as one possible 
mechanism (24).
infection and Malignancy
There are conflicting results on infectious complications after 
ABOi kidney transplantation in the literature. A higher fre-
quency of viral infections such as CMV, HSV, VZV, and BK virus, 
as well as P. jirovecii pneumonia, wound, and severe urinary tract 
infections have been described (22, 25, 26). In the CTS and the 
Heidelberg cohort, an increased risk for early severe infections 
was observed, resulting in approximately one additional patient 
death in 100 ABOi kidney transplant recipients during the 
first year after surgery (15, 23). We and others also observed a 
higher incidence of BK virus replication and BK virus-associated 
nephropathy (23). Of note, in a study by Sharif et  al., the rate 
of BK virus nephropathy was about three times higher in ABOi 
patients compared to patients with HLA antibodies, despite 
comparable immunosuppressive therapy (27). Bentall et  al. 
hypothesized that different blood group antigens may influence 
binding of viral pathogen receptors to sialic acid on renal tubular 
cells (28).
Hall et  al. found no increased cancer risk when comparing 
318 ABOi kidney transplant recipients to matched ABOc controls 
(29). The analysis of 1,420 ABOi transplantations from the CTS 
study also did not show an increased risk of malignancy in ABOi 
compared to ABOc patients (15).
FigURe 2 | Cumulative incidence of (A) death-censored graft survival and (B) patient survival in recipients of an ABO-incompatible (ABOi) living 
donor graft and matched controls receiving an ABO-compatible (ABOc) living donor graft [updated Figure 1 of Ref. (15)]. (C) Cumulative incidence of 
death-censored graft survival in recipients of an ABOi living donor graft with and without anti-CD20 antibody treatment [updated Figure 4 of Ref. (15)]. (D) 
Cumulative incidence of death due to infection in recipients of an ABOi living donor graft and matched controls receiving an ABOc living donor graft [updated Figure 
3 of Ref. (15)].
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Additional Observations
A study from the US Renal Data System registry found a two times 
higher risk of early hemorrhage in 119 ABOi kidney transplant 
recipients when compared to ABOc controls (adjusted HR, 
1.96, P < 0.05) (26). A higher bleeding risk was also found in a 
cohort of pediatric kidney transplant recipients with two major 
bleeding episodes in three patients, which was attributed to the 
unspecific binding of coagulation factors during repeated IA (30). 
This assumption is supported by the findings of de Weerd et al. 
who found a significant correlation between the number of pre-
transplant apheresis treatments and the peri- and posttransplant 
bleeding risk (31).
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Some authors observed an increased rate of surgical complica-
tions after ABOi kidney transplantation, which were attributed to 
early intensified immunosuppression with mycophenolic acid and 
removal of coagulation factors by apheresis. The Freiburg group 
reported a significantly higher number of lymphoceles in ABOi 
patients than in ABOc controls (33 versus 15%; P = 0.003) that 
required surgical revisions in 20 and 8% (P = 0.013) of patients, 
respectively (21). Also, the overall need for surgical revision was 
significantly higher in ABOi patients compared to ABOc controls 
(38 versus 24%, P = 0.032).
FUTURe PeRSPeCTiveS
A new strategy that may come into clinics in the future is the 
reduction of blood group antigen levels in the allograft by ex vivo 
infusion of endo-beta-galactosidase (32).
Another approach is the complete avoidance of the ABO 
antibody barrier by kidney exchange programs. However, 
despite the usage of large kidney exchange programs, including 
the utilization of altruistic donors, the blood group O recipi-
ents accumulated on the waiting list in different studies (33). 
Desensitization for ABOi kidney transplantation was the only 
way to transplant these patients within a reasonable period of 
time.
COnCLUSiOn
In recent years, ABOi kidney transplantation has become a rou-
tine procedure. By this approach, about 30% of living donors who 
were refused in the past can now donate their kidneys and thereby 
significantly expand the living donor pool. Transplantation in 
the presence of major ABO incompatibility, however, places the 
patient at a somewhat higher risk of early rejection, infection, and 
infection-associated death. Therefore, whenever possible, ABOc 
procedures should be preferred.
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